Tromboembolias Múltiplas Associadas a Défice de Anti-Trombina III

A deficiência congénita de anti-trombina III é considerada como um estado de hipercoagulabilidade primária. Os autores apresentam um caso de deficiência de anti-trombina III num jovem do sexo masculino, de 28 anos de idade, com doença valvular aórtica e múltiplos episódios de fenómenos tromboembólicos. Ao discutirem os seus aspectos diagnósticos e terapêuticos, procuram sensibilizar para a necessidade de se rastrear situações de trombofilia em doentes com fenómenos trombóticos recorrentes.

Fístula Arterio-Venosa Cerebral no Recém-Nascido. Uma Causa de Insuficiência Cardíaca Grave

A propósito de dois casos clínicos em que a principal manifestação foi a insuficiência cardíaca congestiva grave relacionada com a existência de fístula arterio-venosa cerebral, os autores salientam a importância do diagnóstico precoce desta doença, se possível ainda antes do nascimento. Uma abordagem multidisciplinar, e uma terapêutica precoce de encerramento da fístula permite contribuir, deste modo, para a redução da morbilidade e da mortalidade associada a esta patologia.

Segmentectomia Pulmonar Anatómica por Videotoracoscopia: Experiência Inicial de um Centro

The use of minimally invasive surgery for the treatment of lung cancer has been growing worldwide. Between May 2008 and November 2012, we performed 24 videothoracoscopic anatomical lung resections in our department. This includes 22 lobectomies and 2 anatomic segmentectomies, which is known to be a more complex surgery, since it demands a finer dissection of sub-lobar structures. We report the clinical cases of two patients who underwent anatomic segmentectomies. The first one was a 63 year old woman, smoker and with a history of breast cancer 20 years earlier. An incidental 9 mm node was found in the lingula. The patient underwent an anatomic lingulectomy and the frozen section was suggestive of a primary lung cancer. Therefore, we proceeded to a full lymphadenectomy. The final pathology evaluation showed a typical carcinoid tumour (pT1aN0). The second patient was a 50 year old woman, a smoker and with a heavy family history of lung cancer. In a screening CT scan a 8 mm ground glass opacity was identified in the left lower lobe (segment VI). After a VATS wedge resection of the node the frozen section evaluation was compatible with adenocarcinoma. We then proceeded to an anatomic segmentectomy with lymphadenectomy. The definitive pathology evaluation confirmed that it was a pT1a N0 bronchioloalveolar adenocarcinoma. The patients now have 5 and 2 months of follow up respectivelly and neither of them has signs of recurrence and the surgical incision showed a good aesthetic result. Anatomic segmentectomy is the indicated surgery especially in patients with low grade tumours, in early stage lung cancers or in patients without pulmonary function for a lobar resection, and it can be done safely using VATS.

Reparação Híbrida do Arco Aórtico: Experiência Inicial do Hospital de Santa Marta

Objectives: To retrospectively review the hybrid treatment of the aortic arch with supra-aortic debranching and endo- vascular stent-graft repair in a single institution. Methods: From 2007 to 2010, all patients submitted to aortic debranching procedures were entered into a prospective database analysis. For the present study, only patients with sealing zones 0 and 1, according to the Ishimaru classification, were included. Procedure-related morbimortality was analysed for the open and endovascular procedures. Results: During the study period, we electively performed 6 total aortic debranching and 4 partial aortic debranching procedures in 10 patients. According to the etiology the indications were: 6 aortic arch aneurysms, 2 post-dissection aneu- rysms, 1 false aneurysm and 1 type I endoleak following TEVAR. The proximal sealing zone was Ishimaru zone 0 in six patients and zone 1 in four patients. The TEVAR procedure was delayed in all patients with a completion success of 80% (1 patient died from ruptured aortic aneurysm; 1 patient denied the second procedure and was lost to follow-up). The 30d mortality rate was 10% (patient mentioned above). The main morbidity was: 1 axillar venous thrombosis, 1 case of subclinical myocardial infarction, 1 case of terminal renal insufficiency and 1 case of prolonged ventilation. No permanent cerebral or peripheral neurologic deficit was noted. Conclusions: The hybrid repair of the aortic arch is a feasible and reproducible procedure, and our results are similar to the previously published series. Medium and long-term results are necessary to confirm whether the technique can be regarded as a safe alternative to open surgery in high-risk patients.

O Volume da Aurícula Esquerda como Marcador Ecocardiográfico de Prognóstico em Doentes com Miocardiopatia Dilatada

Introdução: O aumento da aurícula esquerda (AE) é um marcador de mortalidade na população geral. Os doentes com miocardiopatia dilatada (MCD) têm um amplo espetro de tamanhos deAE, mas a importância clínica desta observação tem sido pouco estudada. Objectivo: Avaliar a importância prognóstica a longo prazo do volume da AE (VAE) em doentes com MCD. Métodos: Estudo prospetivo de doentes admitidos durante o ano de 2004 com o diagnóstico deMCD, em ritmo sinusal. Foi realizado estudo ecocardiográfico completo em repouso e após stress farmacológico. O endpoint composto considerou a assistência ventricular mecânica (AVM), a transplantação cardíaca ou a morte. Resultados: Foram incluídos 35 doentes (68,6% sexo masculino, idade média 52,0), 82,9% etiologia não isquémica. Fração ejeção em repouso 31,1 ± 9,4%.Durante o seguimento, oito doentes morreram, um foi colocado em AVM e um foi transplantado. A análise de Cox univariável revelou potenciais marcadores ecocardiográficos de prognóstico na amostra tais como a dimensão da AE em modo M (HR-1,12; IC: 0,99-1,26;p = 0,067); VAE (HR-1,02; IC: 1,00-1,04; p = 0,046); VAE ajustado à superfície corporal (HR-1,03;IC: 1,00-1,07; p = 0,049); E/A (HR-0,99; IC: 0,99-1,81; p = 0,060); E/A > 2 (HR-7,00; IC:1,48-32,43; p = 0,014) e E/E’ mitral (HR-1,04; IC: 1,00-1,09; p = 0,074). Na análise multivariável a única variável que permaneceu no modelo foi o VAE com o ponto de corte de 63 ml (HR-7,7, IC:0,97-60,61, p = 0,05).Conclusão: Nesta amostra, o VAE foi o único parâmetro ecocardiográfico determinante de AVM,transplantação cardíaca ou morte. Os parâmetros ecocardiográficos habitualmente utilizadospara estratificação de risco, tais como a fração ejeção do ventrículo esquerdo, a dimensão do ventrículo esquerdo e a reserva contrátil não tiveram valor prognóstico na nossa amostra.

Distribuição por Sexos das Cardiopatias Congénitas

Apresenta-se a distribuição por sexos em 4150 crianças, de idade inferior a 13 anos, com cardiopatias congénitas bem definidas, estudadas num periodo de 17 anos. Globalmente a distribuição foi equilibrada, sendo 2108 do fenotipo masculino (50,8%) e 2042 do fenotipo feminino(49,2%), com um quociente Q = 1,03. Verificou-se um predomínio franco do sexo masculino para as seguintes cardiopatias: estenose aórtica valvular e subvalvular fixa (70%), coarctação da aorta(66%), transposição das grandes artérias (60%), coração univentricular (76%), atrésia da tricúspide (63%), anomalia de Ebstein (76%), sindrome do coração esquerdo hipoplásico (85%), aneis vasculares (77%) e estenose médio-ventricular direita (70%). Verificou-se um predomínio franco do sexo feminino para o canal arterial persistente (72%), os defeitos do septo aurículo-ventricular (62%,), a estenose aórtica supravalvular (71%) e a estenose pulmonar infundibular isolada (80%). Confirmou-se uma distribuição muito mais equilibrada para os casos de canal arterial persistente isolado em síndrome de rubéola congénita (56%). Salienta-se a importância de conhecer a distribuição por sexos, por esta ter valor preditivo quanto ao risco de recorrência familiar das cardiopatias congénitas.

Conexão Venosa Pulmonar Anómala. Estudo de Vinte e Quatro Crianças com Angiografia de Subtracção Digital

Objectivo: Avaliar a acuidade da angiografia de subtracção digital (ASD) no diagnóstico morfológico da conexão venosa pulmonar anómala (CVPA) em crianças. Concepção do estudo: Estudo prospectivo de doentes consecutivos entre Janeiro de 1989 e Julho de 1992. Tipo de Atendimento: Serviço de Cardiologia Pediátrica de um Hospital Central. População: Vinte e quatro doentes com CVPA. Métodos: Todos os doentes fizeram avaliação clínica e ecocardiográfica completa (modo M, bidimensional e Doppler) antes da realização do exame hemodinâmico. Em todos os casos se fizeram, de modo sistemático, injecções selectivas de contraste de baixa osmolaridade (0,5-1 ml/kg; dose total <6 mi/kg) no tronco e ramos da artéria pulmonar com registo em angiografia com subtracção digital (ASD). As imagens colhidas foram trabalhadas, selecciona das e armazenadas em video-cassetes e películas fotográficas (câmara multiformato). Resultados: Dezasseis doentes tinham CVPA total (CVPAT): onze à veia cava superior (VCS), dois ao seio coronário e três infradiafragmáticos (dois à veia cava inferior (VCI) e um à veia porta). Oito crianças tinham CVPA parcial (CVPAP): três à VCS, uma à aurícula direita (AD), três à VCI (síndroma da cimitarra) e num caso a CVPA era mista. Em oito doentes (seis com CVPAT e dois com CVPAP), a ASD contribuiu significativamente para o diagnóstico final tendo completado ou corrigido a informação obtida por ecocardiografia. Nos dezoito doentes submetidos a cirurgia cardíaca foi confirmado o diagnóstico obtido por ASD. Conclusões: A ASD é um método muito útil para o diagnóstico anatómico de doentes com CVPA. Na nossa experiência foi particularmente informativa a análise de registos em «video». A ASD está indicada nos casos em que os achados clínicos e ecocardiográficos não sejam típicos.

Safety and Effectiveness of the Genous™ Endothelial Progenitor Cell-Capture Stent in the First Year Following ST-Elevation Acute Myocardial Infarction: A Single Center Experience and Review of the Literature

PURPOSE: The Genous™ stent (GS) is designed to accelerate endothelization, which is potentially useful in the pro-thrombotic environment of ST-elevation acute myocardial infarction (STEMI). We aimed to evaluate the safety and effectiveness of the GS in the first year following primary percutaneous coronary intervention (PCI) and to compare our results with the few previously published studies. METHODS AND MATERIALS: All patients admitted to a single center due to STEMI that underwent primary PCI using exclusively GS, between May 2006 and January 2012, were enrolled. The primary study endpoints were major adverse cardiac events (MACEs), defined as the composite of cardiac death, acute myocardial infarction and target vessel revascularization, at one and 12months. RESULTS: In the cohort of 109 patients (73.4% male, 59 ±12years), 24.8% were diabetic. PCI was performed in 116 lesions with angiographic success in 99.1%, using 148 GS with median diameter of 3.00mm (2.50-4.00) and median length of 15mm (9-33). Cumulative MACEs were 2.8% at one month and 6.4% at 12months. Three stent thromboses (2.8%), all subacute, and one stent restenosis (0.9%) occurred. These accounted for the four target vessel revascularizations (3.7%). At 12months, 33.9% of patients were not on dual antiplatelet therapy. CONCLUSIONS: GS was safe and effective in the first year following primary PCI in STEMI, with an apparently safer profile comparing with the previously published data. SUMMARY: We report the safety and effectiveness of the Genous™ stent (GS) in the first year following primary percutaneous coronary intervention in ST-elevation acute myocardial infarction. A comprehensive review of the few studies that have been published on this subject was included and some suggest a less safe profile of the GS. Our results and the critical review included may add information and reinforce the safety and effectiveness of the GS in ST-elevation in acute myocardial infarction.

Carotid Intima-Media Thickness and Carotid Plaques Improves Prediction of Obstructive Angiographic Coronary Artery Disease in Women

Does carotid intima-media thickness (cIMT), a surrogate marker of cardiovascular events, have predictive incremental value over established risk factors for stable coronary artery disease (CAD)? Prospective study of 300 patients, with suspected stable CAD, admitted for an elective coronary angiography and carotid ultrasound. The CAD patients had a higher cIMT, which showed a modest predictive accuracy for CAD (area under the receiver-operating characteristic curve 0.638, 95% confidence interval 0.576-0.701, P < .001). The cIMT was an independent predictor of CAD, together with age, gender, and diabetes. C-statistic for CAD prediction by traditional risk factors was not significantly different from a model that included cIMT, carotid plaque presence, or both. However, in women, it was significantly increased by the addition of cIMT or carotid plaque presence. Although cIMT cannot be used as a sole indicator of CAD, it should be considered in the panel of investigations that is requested, particularly in women who are candidates for coronary angiography.

Gestão do Risco: Segurança do Doente em Ambiente Hospitalar

A Gestão do Risco e a Segurança do Doente nos hospitais portugueses, começou a dar os primeiros passos no final da década de 90, a partir de projetos voluntários de melhoria da qualidade em saúde, conduzidos pelo King’s Fund e Joint Commission International. Da experiência partilhada e aprendida podemos afirmar que a Gestão do Risco na Saúde é uma metodologia de excelência que contribui para aumentar a segurança de todos. As diferentes estruturas da organização devem manter uma estreita articulação neste processo e a equipa de gestão do risco deve articular com todos os serviços e diversas entidades da organização, designadamente Comissão da Qualidade, Controlo da Infeção Hospitalar, Saúde Ocupacional, Gabinete do Utente, Gabinete Contencioso, Instalações e Equipamentos, Hoteleiros entre outros. No que diz respeito às responsabilidades na gestão do risco, esta é de todos, pois todos os profissionais têm responsabilidades na prevenção de incidentes e na promoção da segurança. A Gestão do Risco assenta em quatro pilares essenciais que devem ser suportados por um programa de formação estruturado para todos os profissionais da organização. Da nossa experiência, estes pilares são a base para a operacionalização de um Programa de Gestão de Risco, sendo eles: - Sistema de Relato de Incidentes - Identificação e Avaliação do Risco - Monitorização de Indicadores de Segurança do Doente - Auditoria como Instrumento de Melhoria Continuia Neste artigo, iremos apenas aprofundar os dois primeiros pilares, baseando-nos na literatura internacional e na nossa experiência como enfermeiras no Centro Hospital de Lisboa Central.

Safety and Effectiveness of the Genous Endothelial Progenitor Cell-Capture Stent: Follow-Up to 5 Years

AIMS: To evaluate the long-term clinical outcomes following percutaneous coronary intervention (PCI) with the Genous stent in an unselected population. METHODS: All patients admitted to a single center who underwent PCI using the GS exclusively, between May 2006 and May 2012, were enrolled, and a clinical follow-up of up to 60 months was carried out. The primary endpoint of major adverse cardiac event (MACE) rate was defined as the composite of cardiac death, acute myocardial infarction (AMI), and target lesion revascularization (TLR). RESULTS: Of the 450 patients included (75.1% male; 65.5 ± 11.7 years), 28.4% were diabetic and acute coronary syndrome was the reason for PCI in 76.4%. Angioplasty was performed in 524 lesions using 597 Genous stents, with angiographic success in 97.1%. At a median of 36 months of follow-up (range, 1-75 months), MACE, AMI, TLR, stent restenosis (SR), and stent thrombosis (ST) rates were 15.6%, 8.4%, 4.4%, 3.8%, and 2.2%, respectively. Between 12 and 24 months, the TLR, SR, and ST rates practically stabilized, up to 60 months. Bifurcation lesions were independently associated with MACE, TLR, and SR. CONCLUSION: This is the first study reporting clinical results with the Genous stent up to 60 months. The Genous stent was safe and effective in the long-term, in an unselected population.

Implante Contraceptivo Não Palpável - Estratégias para a sua Localização e Remoção

Overview and Aims: The contraceptive implant is frequently used to provide contraceptive protection over three years. The implant is inserted into the subcutaneous tissue of the upper arm, and should be palpable and easily removed. We evaluated the best imaging strategy for non-palpable implant (Implanon®) localization and removal. Study Design: Retrospective study. Population: A total of 11 women referred to a tertiary care hospital, between October 2009 and January 2012, for localization and removal of their non-palpable implants. Methods: Different localization methods (ultrasound and magnetic resonance imaging) were evaluated for non-palpable rod. Results: Seven of the nonpalpable implants were inserted in a health care center, three in a district hospital and one in a private clinic. In three women, the reasons for requesting removal were the end of the implant validity, two wanted to become pregnant, two had weight gain, one had weight loss, one referred irregular bleeding, one had two implants and one did a hysterectomy. In 81.8% (9) of the women, the implants were identified and localized by ultrasound, and successfully removed. In two patients the implant was not found and therefore not removed. Conclusions: In our study, high resolution ultrasound proved to be a sensitive method in implants localization, being the primary choice for determining the location of nonpalpable implants.

Pulmonary Hypertension in Portugal: First Data from a Nationwide Registry

Introduction. Pulmonary arterial hypertension (PAH) is a rare disease that must be managed in specialized centers; therefore, the availability of epidemiological national data is critical. Methods. We conducted a prospective, observational, and multicenter registry with a joint collaboration from five centers from Portugal and included adult incident patients with PAH or chronic thromboembolic pulmonary hypertension (CTEPH). Results. Of the 79 patients enrolled in this study, 46 (58.2%) were classified as PAH and 33 patients (41.8%) as CTEPH. PAH patients had a mean age of 43.4 ± 16.4 years. Idiopathic PAH was the most common etiology (37%). At presentation, PAH patients had elevated right atrial pressure (RAP) (7.7 ± 5.9mmHg) and mean pulmonary vascular resistance (11.4 ± 6.5 Wood units), with a low cardiac index (2.7 ± 1.1 L⋅min−1 m−2); no patient was under selective pulmonary vasodilators; however, at follow-up, most patients were on single (50%), double (28%), or triple (9%) combination vasodilator therapy. One-year survival was 93.5%, similar to CTEPH patients (93.9%), that were older (60.0 ± 12.5 years) and had higher RAP (11.0 ± 5.2mmHg,

Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: Four Years of Experience at a Reference Center

INTRODUCTION: We describe our center's initial experience with alcohol septal ablation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy. The procedure, its indications, results and clinical outcomes will be addressed, as will its current position compared to surgical myectomy. OBJECTIVE: To assess the results of ASA in all patients treated in the first four years of activity at our center. METHODS: We retrospectively studied all consecutive and unselected patients treated by ASA between January 2009 and February 2013. RESULTS: In the first four years of experience 40 patients were treated in our center. In three patients (7.5%) the intervention was repeated. Procedural success was 84%. Minor complications occurred in 7.5%. Two patients received a permanent pacemaker for atrioventricular block (6% of those without previous pacemaker). The major complication rate was 5%. There were no in-hospital deaths; during clinical follow-up (22 ± 14 months) cardiovascular mortality was 2.5% and overall mortality was 5%. DISCUSSION AND CONCLUSION: The results presented reflect the initial experience of our center with ASA. The success rate was high and in line with published results, but with room to improve with better patient selection. ASA was shown to be safe, with a low complication rate and no procedure-related mortality. Our experience confirms ASA as a percutaneous alternative to myectomy for the treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy refractory to medical treatment.